Desensitizing drug product

Abstract

Desensitizing drug products, methods of making desensitizing drug products, and methods of using desensitizing drug products including delivery of desensitizing drug products. In one embodiment, the desensitizing drug products are male genital desensitizers that comprise one or anesthetic agents and one or more melting point depressing agents.

What is claimed is: 
     
         1 . A metered spray bottle labeled for the treatment of premature ejaculation in males, wherein the metered spray bottle comprises a male genital desensitizer composition, wherein the male genital desensitizer composition comprises:
 an anesthetic agent;   a first melting point depressing agent selected from the group consisting of thymol, methyl salicylate, phenyl salicylate, butylated hydroxytoluene, butylated hydroxyanisole, S(+)-ibuprofen, R(−)-ibuprofen, cineole, eugenol, capsaicin, eucalyptol, and an alcohol; and   a second melting point depressing agent selected from the group consisting of thymol, methyl salicylate, phenyl salicylate, butylated hydroxytoluene, butylated hydroxyanisole, S(+)-ibuprofen, R(−)-ibuprofen, cineole, eugenol, capsaicin, eucalyptol, and an alcohol, and wherein the second melting point depressing agent is different from the first melting point depressing agent.   
     
     
         2 . A metered spray bottle according to  claim 1 , wherein the anesthetic agent is lidocaine, the first melting point depressing agent is thymol, and the second melting point depressing agent is ethanol. 
     
     
         3 . A metered spray bottle according to  claim 1 , wherein the bottle does not comprise prilocaine. 
     
     
         4 . A metered spray bottle according to  claim 1 , wherein the anesthetic agent is lidocaine. 
     
     
         5 . A method for treating premature ejaculation in males, comprising the step of administering to a male subject a male genital desensitizer composition, wherein the male genital desensitizer composition comprises:
 an anesthetic agent;   a first melting point depressing agent selected from the group consisting of thymol, methyl salicylate, phenyl salicylate, butylated hydroxytoluene, butylated hydroxyanisole, S(+)-ibuprofen, R(−)-ibuprofen, cineole, eugenol, capsaicin, eucalyptol, and an alcohol; and   a second melting point depressing agent selected from the group consisting of thymol, methyl salicylate, phenyl salicylate, butylated hydroxytoluene, butylated hydroxyanisole, S(+)-ibuprofen, R(−)-ibuprofen, cineole, eugenol, capsaicin, eucalyptol, and an alcohol, and wherein the second melting point depressing agent is different from the first melting point depressing agent.   
     
     
         6 . A method according to  claim 5 , wherein the anesthetic agent is lidocaine, the first melting point depressing agent is thymol, and the second melting point depressing agent is ethanol. 
     
     
         7 . A method according to  claim 5 , wherein the bottle does not comprise prilocaine. 
     
     
         8 . A method according to  claim 5 , wherein the anesthetic agent is lidocaine. 
     
     
         9 . A method according to  claim 5 , wherein the administering is performed using a metered spray. 
     
     
         10 . A method according to  claim 9 , wherein the administering comprises 3 to 10 sprays.